Luminex Corp. Launches Its First Pharmacogenomics Test for Personalized Medicine
Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Having a detailed overview of the patient’s life and health could aid in determining the mechanisms that caused a disease to develop.
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
Copyright © 2024 | WordPress Theme by MH Themes